Keratoprosthesis in autoimmune disease

Ocular Immunology and Inflammation

Volumn 18, Issue 4, 2010, Pages 275-280

  Ciralsky, Jessica ^a   Papaliodis, George N ^a   Foster, C Stephen ^b   Dohlman, Claes H ^a   Chodosh, James ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

Autoimmune disease; Keratoprosthesis; Mucous membrane pemphigoid; Stevens Johnson syndrome

Indexed keywords

ANTIFUNGAL AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; ALLERGIC REACTION; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; B SCAN; BLINDNESS; CASE REPORT; CORNEA DISEASE; CORNEA NECROSIS; CORNEA TRANSPLANTATION; DRUG HYPERSENSITIVITY; ENDOLEAK; EXTRACAPSULAR CATARACT EXTRACTION; FEMALE; FEVER; GRAFT REJECTION; HUMAN; IMMUNOPATHOGENESIS; INTRAOCULAR PRESSURE; KERATITIS; KERATOPROSTHESIS; MALE; MEDICAL RECORD REVIEW; MUCOUS MEMBRANE PEMPHIGOID; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PROSTHESIS INFECTION; RASH; REOPERATION; REPEAT PROCEDURE; RETROSPECTIVE STUDY; SLIT LAMP; TOXIC EPIDERMAL NECROLYSIS; VISUAL ACUITY;

ADULT; ALTERNARIA; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BLINDNESS; CORNEAL DISEASES; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYCOSES; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PREDNISOLONE; PROSTHESES AND IMPLANTS; PROSTHESIS IMPLANTATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77954870593     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273941003682300     Document Type: Article

References (38)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001:79:214-221.
2. Thompson RW Jr, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003:110:1396-1402.
3. Sayegh RR, Ang LP, Foster CS, et al. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol. 2008:145:438-444.
4. Zerbe BL, Belin MW, Ciolino JB. Boston Type 1 Keratoprosthesis Study Group. Results from the multicenter Boston Type 1 Keratoprosthesis Study. Ophthalmology. 2006:113:1779.e1-e7.
5. Aldave AJ, Kamal KM, Vo RC, et al. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009:116:640-651.
6. Bradley JC, Hernandez EG, Schwab IR, et al. Boston type I keratoprosthesis: the University of California Davis experience. Cornea. 2009:28:321-327.
7. Chew HF, Ayres BD, Hammersmith KM, et al. Boston keratoprosthesis outcomes and complications. Cornea. 2009 Aug 29 (epub ahead of print).
8. Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001:20:19-23.
9. Dudenhoefer EJ, Nouri M, Gipson IK, et al. Histopathology of explanted collar button keratoprostheses: a clinicopathologic correlation. Cornea. 2003:22:424-428.
10. Stoiber J, Csaky D, Schedle A, et al. Histopathologic findings in explanted osteo-odontokeratoprosthesis. Cornea. 2002:21:400-404.
11. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens- Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 2005:94:419-436.
12. Long M, Rack HJ. Titanium alloys in total joint replacement- a materials science perspective. Biomaterials. 1998:19:1621-1639.
13. Lloyd AW, Faragher RG, Denyer SP. Ocular biomaterials and implants. Biomaterials. 2001:22:769-785.
14. Lisowska B, Maslinski W, Maldyk P, et al. The role of cytokines in inflammatory response after total knee arthroplasty in patients with rheumatoid arthritis. Rhematol Int. 2008:28:667-671.
15. Gualini F, Berglundh T. Immunohistochemical characteristics of inflammatory lesions at implants. J Clin Periodontol. 2003:30:14-18.
16. Bullon P, Fioroni M, Goteri G, et al. Immunohistochemical analysis of soft tissues in implants with healthy and peri- implantitis condition, and aggressive periodontitis. Clin Oral Implants Res. 2004:15:553-559.
17. Borsani E, Salgarello S, Stacchiotti A, et al. Altered immunolocalization of heat-shock proteins in human peri-implant gingiva. Acta Histochem. 2007:109:221-227.
18. Konttinen YT, Lappalainen R, Laine P, et al. Immunohistochemical evaluation of inflammatory mediators in failing implants. Int J Periodontics Restorative Dent. 2006:26:135-141.
19. Leung KC, McMillan AS, Cheung BP, et al. Sjögren's syndrome sufferers have increased oral yeast levels despite regular dental care. Oral Dis. 2008:14:163-173.
20. Nalepka JL, Lee MJ, Kraay MJ, et al. Lipopolysaccharide found in aseptic loosening of patients with inflammatory arthritis. Clin Orthop Relat Res. 2006:451:229-235.
21. Engesaeter LB, Lie SA, Espehaug B, et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2003:74:644-651.
22. Chadha HS, Wooley PH, Sud S, et al. Cellular prolieferation and cytokine responses to polymethylmethacrylate particles in patients with a cemented total joint arthroplasty. Inflamm Res. 1995:44:145-151.
23. Gil-Albarova J, Lacleriga A, Barrios C, et al. Lymphocyte response to polymethylmethacrylate in loose total hip prostheses. J Bone Joint Surg Br. 1992:74:825-830.
24. Willert HG, Bertram H, Buchhorn GH. Osteolysis in alloarthroplasty of the hip: the role of bone cement fragmentation. Clin Orthop Relat Res. 1990:258:108-121.
25. Toumbis CA, Kronick JL, Wooley PH, et al. Total joint arthroplasty and the immune response. Semin Arthritis Rheum. 1997:27:44-47.
26. Letko E, Bhol K, Colon C, et al. Biology of interleukin-5 in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol. 2002:240:565-569.
27. Lee SJ, Li Z, Sherman B, et al. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1993:34:3522-3525.
28. Kumari S, Bhol KC, Rehman F, et al. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Cytokine. 2001:14:218-224.
29. Elder MJ, Dart JK, Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid-the role of cytokines. Exp Eye Res. 1997:65:165-176.
30. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004:123:850-855.
31. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis, J Invest Dermatol. 2002:118, 728-733
32. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000:47: 85-118.
33. Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009:28:117-144.
34. Dohlman JG, Foster CS, Dohlman CH. Boston Keratoprosthesis in Stevens-Johnson syndrome: a case of using infliximab to prevent tissue necrosis. D J Ophthalmol. 2009:15:1-5.
35. Gregory DG. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocul Surf. 2008:6:87-95.
36. Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008:6:128-142.
37. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci. 2009:50:3346-3352.
38. Ament JD, Stryjewski TP, Ciolino JB, et al. Cost-effectiveness of the Boston keratoprosthesis. Am J Ophthalmol. 2009 Nov 23 (epub ahead of print).